Last updated 15 days ago
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
632 patients around the world
Available in Argentina
Bristol-Myers Squibb
7Research sites
632Patients around the world
This study is for people with
Kidney cancer
Clear Cell Renal Cell Carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Hospital Asociación de Beneficencia Hospital Sirio Libanes - CABA, Buenos Aires
Recruiting
Instituto Oncológico de Córdoba IONC - Fundación Richardet Longo
Recruiting
Centro Privado de RMI Río Cuarto
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto de Nefrología Pergamino SRL
Recruiting
StudyCheckMate-67T
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Clear Cell Renal Cell CarcinomaKidney cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04810078
